Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Recommendation of "Buy" from Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) has been given a consensus recommendation of "Buy" by the fifteen research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $47.15.

A number of research firms have recently issued reports on DYN. JPMorgan Chase & Co. reduced their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Piper Sandler dropped their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a report on Friday, February 28th. HC Wainwright cut their target price on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Scotiabank initiated coverage on Dyne Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price target for the company. Finally, Chardan Capital reiterated a "buy" rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a report on Friday, May 9th.

Institutional Investors Weigh In On Dyne Therapeutics

Large investors have recently bought and sold shares of the stock. Rhumbline Advisers boosted its stake in shares of Dyne Therapeutics by 4.2% in the 1st quarter. Rhumbline Advisers now owns 133,627 shares of the company's stock valued at $1,398,000 after buying an additional 5,383 shares during the period. Optimize Financial Inc purchased a new position in Dyne Therapeutics in the first quarter worth approximately $154,000. Exome Asset Management LLC acquired a new position in Dyne Therapeutics during the 1st quarter worth approximately $2,703,000. Caxton Associates LLP purchased a new stake in shares of Dyne Therapeutics in the 1st quarter valued at approximately $157,000. Finally, Voleon Capital Management LP purchased a new stake in shares of Dyne Therapeutics in the 1st quarter valued at approximately $624,000. Hedge funds and other institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Stock Down 3.4%

NASDAQ:DYN traded down $0.42 on Thursday, reaching $11.82. The company's stock had a trading volume of 1,132,995 shares, compared to its average volume of 1,630,026. Dyne Therapeutics has a 12-month low of $6.36 and a 12-month high of $47.45. The stock has a 50 day moving average price of $10.30 and a 200 day moving average price of $16.33. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -3.32 and a beta of 1.19.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.17). Equities research analysts expect that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.